Renal involvement in type I cryoglobulinemia is uncommon, and management of such disease is difficult and remains poorly defined. Pandrangi and colleagues describe their experience of using rituximab—a chimeric anti-CD20 monoclonal antibody that selectively depletes CD20+B cells—as a novel approach for treating the renal disease of a patient with type I cryoglobulinemia-associated glomerulonephritis.
- Sushma Pandrangi
- Atul Singh
- Noreen F Rossi
